Cart (0 Items)
Your cart is currently empty.
View ProductsIt looks like you are visiting from outside the EU. Switch to the US version to see local pricing in USD and local shipping.
Switch to US ($)
| Size | 100ug, 1MG |
|---|---|
| Isotype | IgG2, kappa |
| Brand | ProteoGenix |
| Product type | Primary Antibodies |
| Clonality | Monoclonal Antibody |
| Expression system | Mammalian cells |
| Applications | Elisa, WB |
| Product name | Tremelimumab Biosimilar - Anti-CTLA4, CD152 mAb - Research Grade |
|---|---|
| Source | CAS 745013-59-6 |
| Species | Homo sapiens |
| Expression system | Mammalian cells |
| Purity | >85% |
| Buffer | PBS buffer PH7.5 |
| Delivery condition | Blue ice (+4°C) |
| Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
| Storage condition | store at -80°C |
| Brand | ProteoGenix |
| Aliases /Synonyms | Tremelimumab,Ticilimumab, CP-675,CP-675,206,CP-675206 clone 11.2.1,CTLA4, CD152,anti-CTLA4, CD152 |
| Reference | PX-TA1177 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype | IgG2-kappa |
| Clonality | Monoclonal Antibody |
Tremelimumab is studied for the treatment of Mesothelioma, Liver Neoplasms, Liver Cancer, Liver Cell Caricinoma, and HepatoCellular Carcinoma.
Tremelimumab Biosimilar - Anti-CTLA4, CD152 mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.
Immobilized CD152 Recombinant Protein (cat. No.PX-P4108) at 0.5µg/mL (100µL/well) can bind to Tremelimumab Biosimilar - Anti-CTLA4, CD152 mAb (cat. No.PX-TA1177) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450
Related products
Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.
Reviews
There are no reviews yet.